Ensysce Biosciences (ENSCW) Non-cash Items (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Non-cash Items of $64768.0 for Q3 2025, down 88.84% year-over-year from $580414.0 in Q3 2024, and up 25.14% quarter-over-quarter from $51758.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Non-cash Items (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Non-cash Items data on file, last reported at $64768.0 in Q3 2025.
- Non-cash Items for Q3 2025 came in at $64768.0, down 88.84% year-over-year; the trailing twelve-month figure through Sep 2025 was $64768.0 (down 88.84% YoY), and the FY2024 annual result was $38734.0, down 93.32% from the prior year.
- Non-cash Items improved to $64768.0 in Q3 2025 per ENSCW's latest filing, from $51758.0 in the prior quarter.
- Over five years, Non-cash Items peaked at $10.2 million in Q4 2021 and troughed at $23922.0 in Q1 2023.
- A 5-year average of $1.8 million and a median of $431873.5 in 2022 frame the typical range for Non-cash Items.
- The sharpest annual moves came in 2023 and 2024: Non-cash Items plunged 99.57% in 2023, then surged 2324.38% in 2024.
- A 5-year view of Non-cash Items shows it stood at $10.2 million in 2021, then sank by 97.26% to $279306.0 in 2022, then jumped by 107.56% to $579733.0 in 2023, then plunged by 93.32% to $38734.0 in 2024, then soared by 67.21% to $64768.0 in 2025.
- Business Quant data shows ENSCW's Non-cash Items at $64768.0 in Q3 2025, $51758.0 in Q2 2025, and $38749.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ensysce Biosciences | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 64,768.00 |
| Sep 30, 2025 | 64,768.00 |
| Jun 30, 2025 | 51,758.00 |
| Jun 30, 2025 | 51,758.00 |
| Mar 31, 2025 | 38,749.00 |
| Mar 31, 2025 | 38,749.00 |
| Dec 31, 2024 | 38,734.00 |
| Dec 31, 2024 | 38,734.00 |
| Sep 30, 2024 | 580,414.00 |
| Sep 30, 2024 | 580,414.00 |
| Jun 30, 2024 | 580,188.00 |
| Jun 30, 2024 | 580,188.00 |
| Mar 31, 2024 | 579,960.00 |
| Mar 31, 2024 | 579,960.00 |
| Dec 31, 2023 | 579,733.00 |
| Dec 31, 2023 | 579,733.00 |
| Sep 30, 2023 | 24,505.00 |
| Sep 30, 2023 | 24,505.00 |
| Jun 30, 2023 | 24,282.00 |
| Jun 30, 2023 | 24,282.00 |